US20210130362A1 - Medical use of compound iii - Google Patents
Medical use of compound iii Download PDFInfo
- Publication number
- US20210130362A1 US20210130362A1 US17/145,430 US202117145430A US2021130362A1 US 20210130362 A1 US20210130362 A1 US 20210130362A1 US 202117145430 A US202117145430 A US 202117145430A US 2021130362 A1 US2021130362 A1 US 2021130362A1
- Authority
- US
- United States
- Prior art keywords
- disorder
- schizophrenia
- compound iii
- compound
- psychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title description 97
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 124
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 77
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 54
- 208000027674 Schizophrenia Spectrum and Other Psychotic disease Diseases 0.000 claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 claims description 28
- 206010007776 catatonia Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 230000002238 attenuated effect Effects 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 208000020016 psychiatric disease Diseases 0.000 claims description 15
- 208000022610 schizoaffective disease Diseases 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 208000021465 Brief psychotic disease Diseases 0.000 claims description 11
- 208000024254 Delusional disease Diseases 0.000 claims description 11
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 11
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 11
- 230000000561 anti-psychotic effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 47
- 201000010099 disease Diseases 0.000 abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 16
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 47
- 208000024891 symptom Diseases 0.000 description 32
- 239000003826 tablet Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 229920002785 Croscarmellose sodium Polymers 0.000 description 18
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 18
- 229960001681 croscarmellose sodium Drugs 0.000 description 16
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 15
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 15
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 11
- 239000007941 film coated tablet Substances 0.000 description 11
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 229960001021 lactose monohydrate Drugs 0.000 description 11
- 238000000634 powder X-ray diffraction Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000002411 adverse Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229940124604 anti-psychotic medication Drugs 0.000 description 9
- 239000008120 corn starch Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 229920000881 Modified starch Polymers 0.000 description 8
- 238000001237 Raman spectrum Methods 0.000 description 8
- 206010042458 Suicidal ideation Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 208000004547 Hallucinations Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010012239 Delusion Diseases 0.000 description 6
- BZTIJCSHNVZMES-UHFFFAOYSA-N O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 Chemical compound O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 BZTIJCSHNVZMES-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 231100000868 delusion Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000001069 Raman spectroscopy Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010065604 Suicidal behaviour Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 235000013980 iron oxide Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 101000581533 Homo sapiens Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102100027320 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009478 high shear granulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- LEFSNWUSTYESGC-UHFFFAOYSA-N 5-amino-1h-pyrazole-4-carboxamide Chemical compound NC(=O)C1=CNN=C1N LEFSNWUSTYESGC-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- GBHWOSQHZMREGQ-UHFFFAOYSA-N COC(=O)CC1=CC=CC=N1.I.II.NC(=O)C1=C(N)N(C2CCOCC2)N=C1.O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 Chemical compound COC(=O)CC1=CC=CC=N1.I.II.NC(=O)C1=C(N)N(C2CCOCC2)N=C1.O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 GBHWOSQHZMREGQ-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- UUOZPCUEGSNTAQ-UHFFFAOYSA-N O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1.O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 Chemical compound O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1.O=C1NC(CC2=NC=CC=C2)=NC2=C1C=NN2C1CCOCC1 UUOZPCUEGSNTAQ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- ORAKNQSHWMHCEY-UHFFFAOYSA-N methyl 2-pyridin-2-ylacetate Chemical compound COC(=O)CC1=CC=CC=N1 ORAKNQSHWMHCEY-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 1
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UIKWDDSLMBHIFT-WKIKZPBSSA-N 2-[4-[(3z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethyl decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 UIKWDDSLMBHIFT-WKIKZPBSSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 206010018671 Grandiosity Diseases 0.000 description 1
- GUTXTARXLVFHDK-UHFFFAOYSA-N Haloperidol decanoate Chemical compound C1CC(OC(=O)CCCCCCCCC)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 GUTXTARXLVFHDK-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229940076380 PDE9 inhibitor Drugs 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 206010042635 Suspiciousness Diseases 0.000 description 1
- 238000001772 Wald test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229960001615 asenapine maleate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960005007 haloperidol decanoate Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940008015 lithium carbonate Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 229960002863 lurasidone hydrochloride Drugs 0.000 description 1
- NEKCRUIRPWNMLK-SCIYSFAVSA-N lurasidone hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 NEKCRUIRPWNMLK-SCIYSFAVSA-N 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 239000013080 microcrystalline material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229960000635 paliperidone palmitate Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000769 periciazine Drugs 0.000 description 1
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- BMXXSXQVMCXGJM-UHFFFAOYSA-N pipamperone dihydrochloride Chemical compound [Cl-].[Cl-].C1CC(C(=O)N)([NH+]2CCCCC2)CC[NH+]1CCCC(=O)C1=CC=C(F)C=C1 BMXXSXQVMCXGJM-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960005197 quetiapine fumarate Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960003474 ziprasidone hydrochloride Drugs 0.000 description 1
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to compound III for the use in the treatment of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases like first episode of psychosis (FEP), relapses of these diseases like reduction of relapse in patients with schizophrenia (REX), polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
- FEP first episode of psychosis
- REX relapses of these diseases like reduction of relapse in patients with schizophrenia
- polymorphs of compound III and pharmaceutical compositions comprising compound III and/or its polymorphs.
- Schizophrenia spectrum and other psychotic disorders include schizophrenia, psychosis, other psychotic disorders, and schizotypal (personality) disorder. Furthermore they include delusional disorder, attenuated psychosis syndrome, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, other specified schizophrenia spectrum and other psychotic disorder, unspecified schizophrenia spectrum and other psychotic disorder, catatonia associated with another mental disorder (catatonia specifier), and catatonic disorder due to another medical condition.
- a first episode of psychosis is the first time a person experiences a psychotic episode.
- Schizophrenia is a chronic, severe, and disabling brain disorder affecting about one percent of the world's general population. Schizophrenia affects men and women equally. It occurs at similar rates in all ethnic groups around the world. Despite advances in the treatment of schizophrenia over the past decades, the illness continues to be associated with poor outcomes. These poor outcomes are in part due to identification and intervention late in the course of the illness, thus making it more challenging to reverse.
- a first episode is a first manifestation of the disorder meeting the defining diagnostic symptom criteria.
- Relapse in schizophrenia is defined as the reoccurrence of previously treated psychotic symptoms and may include hallucinations, delusions, strong and inappropriate emotions, and disordered thought. It is also defined as any of the following: re-hospitalization for psychiatric illness, or emergency room (ER) visits for psychiatric illness, clinical worsening, or clinical worsening as assessed by Positive and Negative Syndrome Scale (PANSS), or worsening suicidal ideation and behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). In the course of the illness most patients with schizophrenia experience multiple relapses which are characterized by acute psychotic exacerbation (DSM-V).
- DSM-V acute psychotic exacerbation
- WO 2009/121919 discloses a number of pyrazolopyrimidinones as potent PDE9 inhibitors. Among others, WO 2009/121919 discloses compound III
- WO 2009/121919 generically discloses that the compounds exemplified therein may be used in the treatment of cognitive impairment related to several diseases.
- compound III has surprisingly been found to fulfil the above mentioned criteria required for use in the treatment of:
- compound III can be used in the treatment of first episodes of:
- compound III can be used in the treatment of relapses of:
- compound III can be used in the prevention/delay of:
- compound III can be used in the prevention/delay of first episodes and/or relapses of above mentioned diseases, conditions and symptoms.
- compound III can be used in the treatment of schizophrenia by disease stabilization, schizophrenia by reducing the severity of relapses, schizophrenia by prevention of relapses, or schizophrenia by delaying relapses.
- compound III can be used in the treatment of symptoms of above mentioned diseases, conditions and symptoms.
- compound III can be used in the treatment of:
- compound III can be used in the prevention/delay of first episodes and/or relapses of above mentioned symptoms.
- FIG. 1 shows the X-ray powder diffraction pattern of Compound IIIa.
- FIG. 2 shows the X-ray powder diffraction pattern of Compound IIIb.
- FIG. 4 shows the Raman spectrum of Compound IIIb.
- FIG. 5 shows the dissolution profiles of core tablets and film-coated tablets containing 50 mg of Formulation 2 (Table 5 and Table 6) produced from milled drug substance.
- the present invention provides compound III:
- the present invention provides compound III for use in the treatment of first episodes of:
- the present invention provides compound III for use in the treatment of relapses of:
- the present invention provides compound III for use in the prevention/delay of:
- the present invention provides compound III for use in the prevention/delay of first episodes and/or relapses of above mentioned diseases, conditions and symptoms.
- the present invention provides compound III for use in the treatment of schizophrenia by disease stabilization, schizophrenia by reducing the severity of relapses, schizophrenia by prevention of relapses, or schizophrenia by delaying relapses.
- the present invention provides compound III for use in the treatment of reduction of relapse in patients with schizophrenia receiving antipsychotic therapy.
- the present invention provides compound III for use in the treatment of attenuated psychosis syndrome.
- the present invention provides compound III for use in the prevention of first episode psychosis in individuals with attenuated psychosis syndrome.
- the present invention provides compound III for use in the treatment of:
- the present invention provides compound III for use in the treatment of first episodes and/or relapses of above mentioned symptoms.
- the present invention provides compound III for use in the prevention/delay of first episodes and/or relapses of above mentioned symptoms.
- the present invention provides compound III according to any one of the preceding aspects, characterized in that compound III is administered in addition to treatment with another antipsychotic drug.
- the present invention provides compound III according to any one of the preceding aspects, characterized in that the antipsychotic drug is selected from the group consisting of Aripiprazole, Risperidone, Quetiapine fumarate, Olanzapine, Paliperidone, Lurasidone hydrochloride, Haloperidol, Paliperidone palmitate, Ziprasidone hydrochloride, Quetiapine, Ziprasidone, Blonanserin, Chlorpromazine hydrochloride, Amisulpride, Haloperidol decanoate, Lithium carbonate, Asenapine maleate, Sulpiride, Chlorpromazine, Flupentixol, Fluphenazine decanoate, Flupentixol decanoate, Fluphenazine, Fluphenazine hydrochloride, Iloperidone, Levomepromazine, Levosulpiride, Loxapine, Lurasidone, Periciazine, Peros
- the present invention provides compound III according to any one of the preceding aspects, characterized in that 10, 25, 50 or 100 mg of compound III are administered.
- WO 2009/121919 discloses the synthesis of compound IIIa.
- compound IIIb another polymorphic form, compound IIIb, exists.
- Both compound IIIa and compound IIIb, respectively, can be synthesized in pure form.
- Compound IIIa was obtained in a purity >95% (ratio between compound IIIa and compound IIIb >95:5 based on XRPD) as well as compound IIIb in a purity >95% (ratio between compound IIIb and compound IIIa >95:5 based on XRPD).
- both compound IIIa and compound IIIb are characterized by its corresponding XRPD and Raman data.
- compound IIIa refers to crystalline form a of Compound III.
- compound IIIb refers to crystalline form b of Compound III.
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at the following 2-theta values measured using monochromatic CuK ⁇ 1 radiation of ⁇ 1.54056 ⁇ , 40 kV, 40 mA: 7.7° ⁇ 0.2° and 9.0° ⁇ 0.2°.
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at any one or all of the following 2-theta values measured using monochromatic CuK ⁇ 1 radiation of ⁇ 1.54056 ⁇ , 40 kV, 40 mA: 17.3° ⁇ 0.2°, 21.3° ⁇ 0.2°, 20.9° ⁇ 0.2°, 23.3° ⁇ 0.2°, 9.0° ⁇ 0.2°, 14.7° ⁇ 0.2°, 7.7° ⁇ 0.2°.
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at the following 2-theta values measured using monochromatic CuK ⁇ 1 radiation of ⁇ 1.54056 ⁇ , 40 kV, 40 mA: 7.7° ⁇ 0.2° and 9.0° ⁇ 0.2°, and the Raman spectrum comprises peaks at any one or all of the following Raman shifts expressed in wavenumbers in cm ⁇ 1 : 1190 ⁇ 2, 1401 ⁇ 2, 1675 ⁇ 2.
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >75% (ratio between compound IIIa and compound IIIb >75:25 based on XRPD).
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >90% (ratio between compound IIIa and compound IIIb >90:10 based on XRPD).
- the polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >95% (ratio between compound IIIa and compound IIIb >95:5 based on XRPD).
- the present invention provides compound IIIb having a purity >20% (ratio between compound IIIb and compound IIIa >20:80 based on XRPD).
- the present invention provides compound IIIb having a purity >40% (ratio between compound IIIb and compound IIIa >40:60 based on XRPD).
- the present invention provides compound IIIb having a purity >70% (ratio between compound IIIb and compound IIIa >70:30 based on XRPD).
- the present invention provides compound IIIb having a purity >75% (ratio between compound IIIb and compound IIIa >75:25 based on XRPD).
- the present invention provides compound IIIb having a purity >80% (ratio between compound IIIb and compound IIIa >80:20 based on XRPD).
- the present invention provides compound IIIb having a purity >90% (ratio between compound IIIb and compound IIIa >90:10 based on XRPD).
- the present invention relates to compound III, compound IIIa, compound IIIb or mixtures thereof for use in the treatment of above mentioned diseases, conditions and symptoms.
- Another aspect of the present invention relates to the pharmaceutical composition
- the pharmaceutical composition comprising compound III, IIIa or IIIb or a mixture thereof and hydroxypropyl cellulose and/or croscarmellose sodium.
- the present invention relates to the pharmaceutical composition
- the pharmaceutical composition comprising corn starch and hydroxypropyl cellulose and/or croscarmellose sodium.
- the present invention relates to the pharmaceutical composition
- the pharmaceutical composition comprising lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and pregelatinized starch or corn starch.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a tablet core consisting of compound III, lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and pregelatinized starch or corn starch.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a tablet core consisting of 1-30% (wt/wt) compound III, 63-83% (wt/wt) lactose monohydrate, 5-25% (wt/wt) pregelatinized starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a tablet core consisting of 8-24% (wt/wt) compound III, 53-70% (wt/wt) lactose monohydrate, 10-20% (wt/wt) pregelatinized starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a tablet core consisting of 1-30% (wt/wt) compound III, 50-80% (wt/wt) lactose monohydrate, 5-20% (wt/wt) corn starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a tablet core consisting of 8-24% (wt/wt) compound III, 65-75% (wt/wt) lactose monohydrate, 5-20% (wt/wt) corn starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- Another aspect of the present invention relates to a pharmaceutical composition as defined above for use in the above mentioned diseases, conditions and symptoms.
- Another aspect of the present invention relates to a method of treatment of above mentioned diseases, conditions and symptoms.
- compound III relates to the compound of the following structure
- Subject means a human patient.
- AE adverse event
- Adverse event means any AE which resulted in death, was immediately life-threatening, resulted in persistent or significant disability/incapacity, required or prolonged patient hospitalisation, was a congenital anomaly/birth defect, or was to be deemed serious for any other reason if it was an important medical event when based upon appropriate medical judgement which might jeopardise the patient and might require medical or surgical intervention to prevent one of the other outcomes listed in the above definitions.
- HPMC hypromellose hydroxypropylmethylcellulose
- IDR intrinsic dissolution rate intrinsic solubility i.v. intravenous M mole, mol/L
- the standard error range for the 2-theta values is ⁇ 0.2°.
- 5-Amino-1H-pyrazole-4-carboxylic acid amide I (64.0 kg, 304.4 mol) and 2-pyridineacetic acid methyl ester II (69.1 kg, 457.1 mol) are suspended in tert.-Amyl alcohol (84 kg) and heated to 80-90° C.
- a solution of potassium tert.-amylate (25% in toluene, 230.6 kg, 457.1 mol) is added at 80-90° C.
- the dropping funnel is rinsed with toluene (84 kg).
- the reaction mixture is heated to reflux. After complete conversion the mixture is cooled down to 55-65° C. and water (192 kg) is added to the reaction mixture.
- crystallization can be initiated by seeding with compound IIIa prior to addition of the second portion acetic acid.
- 5-Amino-1H-pyrazole-4-carboxylic acid amide I (50.0 kg, 237.8 mol) and 2-pyridineacetic acid methyl ester II (53.9 kg, 356.6 mol) are suspended in tert.-Amyl alcohol (65.6 kg) and heated to 80-90° C.
- a solution of potassium tert.-amylate (25% in toluene, 180.2 kg, 356.6 mol) is added at 80-90° C.
- the dropping funnel is rinsed with toluene (43.5 kg).
- the reaction mixture is heated to reflux. After complete conversion the mixture is cooled down to 55-65° C. and water (150 kg) is added to the reaction mixture. The mixture is cooled down to 15-25° C.
- Compound IIIa or IIIb (crude, form a or form b) (44.5 kg, 142.9 mol) is suspended in ethanol (474 kg) and water (13.4 kg). The mixture is heated to reflux and stirred for 45 min. The solution is cooled to 72-78° C. and polish filtered. The filter is rinsed with ethanol (54 kg). The mixture is cooled to 58-65° C. Optionally, crystallization can be initiated by seeding with compound IIIa (form a) after cooling to 58-65° C. The mixture is cooled to 0-10° C. The suspension is filtered and the filter cake washed with ethanol (70 kg). The isolated material is dried at max. 60° C. to give Compound IIIa (unmilled, form a) (37.8-42.3 kg, 85-95%).
- Compound IIIa or IIIb (crude, form a or form b) (2.2 kg, 7.1 mol) is suspended in ethanol (4.4 L) and water (7.7 L) at room temperature.
- Aqueous sodium hydroxide (45%, 691 g, 7.7 mol) is added via a pump keeping the internal temperature at 15-25° C.
- the pump is rinsed with water (1.1 L) and the reaction mixture stirred at room temperature for 35 min.
- Acetic acid (515 g, 8.4 mol) is added via a pump keeping the internal temperature at 15-25° C.
- the pump is rinsed with ethanol (1.1 L) and the reaction mixture stirred at room temperature for 75 min.
- the suspension is filtered and the filter cake washed with water (8.8 kg).
- the isolated material is dried at max. 60° C. to give Compound IIIb (unmilled, form b) (2.0 kg, 92%).
- micronization was performed using the pilot plant opposed jet mill 140 AFG (Hosokawa-Alpine AG, Augsburg) applying the following process parameters for Compound IIIa (unmilled, form a):
- a particle size distribution in terms of x90 ⁇ 28 ⁇ m was achieved.
- laser diffraction/dry dispersion Sympatec was used for analysis.
- the Compounds IIIa and IIIb are white microcrystalline materials.
- Compound IIIa is highly crystalline as can be seen in the X-ray powder diffraction diagram in FIG. 1 and RAMAN spectrum in FIG. 3 .
- the ratio of a mixture containing compound IIIa (crude, form a) and a certain amount of compound IIIb (crude, form b) did not change after storage under ambient conditions for 28 months.
- RAMAN spectrum (characteristic bands) [cm ⁇ 1 ]: 1190 ⁇ 2, 1401 ⁇ 2 and 1675 ⁇ 2.
- Compound IIIb is highly crystalline as can be seen in the X-ray powder diffraction diagram in FIG. 2 and RAMAN spectrum in FIG. 4 .
- RAMAN spectrum (characteristic bands) [cm ⁇ 1 ]: 1182 ⁇ 2, 1394 ⁇ 2 and 1663 ⁇ 2.
- the pharmaceutical composition according to the invention is a tablet for oral administration comprising a core, containing compound III, IIIa or IIIb or a mixture thereof and hydroxypropyl cellulose and/or croscarmellose sodium, and further comprising a film coating, enveloping said core.
- the dissolution profiles of core tablets and film-coated tablets 50 mg are shown in FIG. 5 .
- a pharmaceutical composition comprising compound III, IIIa or IIIb or a mixture thereof in combination with hydroxypropyl cellulose and/or croscarmellose sodium leads to adjustment of the drug load to the same level for all dose strengths, and a fast dissolution of the tablet can be reached irrespective of the low intrinsic dissolution rate of compound III in the physiologically relevant pH range above pH 4.
- Formulation 1 and formulation 2 can be obtained by using either compound IIIa or compound IIIb or mixtures thereof, respectively.
- the formulation 1 is preferably produced using the following equipment:
- the formulation 2 is preferably produced using the following equipment:
- the granulation liquid for the wet granulation process is prepared.
- Purified water of about 10-90° C. is filled into a suitable mixing vessel.
- a binding agent such as hydroxypropyl cellulose or hypromellose is stirred in, and the dispersion is cooled down if necessary to room temperature. If necessary, the liquid is allowed to stand overnight (completeness of solution/degassing) and stirred up before use. If necessary, any weight loss is compensated with purified water.
- the dry matter (solid content) of this granulation liquid is preferrably in the range of 4-7% (wt/wt, assuming feasibility for a range of 2-10%, wt/wt).
- Both formulations 1 and 2 may be produced by high shear or fluid bed granulation.
- the preferred production process is described below, but the production of each formulation using either equipment leads to reasonable drug product.
- the selection of the granulation process depends on available equipment and on economic decisions.
- the required quantity of compound III active ingredient (depending on the dose strength), lactose monohydrate, corn starch or pregelatinized starch, and mannitol (optionally) are filled in the product bowl of a high-shear mixer/granulator, then mixed homogeneously for about 3-4 min using impeller and chopper blades.
- the granulation liquid is added either manually or by spray nozzles and the wet mass is granulated for about 2-3 min, again using impeller and chopper blades.
- the wet granules are wet-screened through a 3.0 mm mesh size sieve to destroy large agglomerates.
- the wet-screened material is transferred to a conventional fluid bed drier (or alternatively to a tray drier) and dried at an inlet air temperature of approximately 60-90° C.
- Granules are dried when the water activity of the resulting dry granules is below 0.6.
- the dried granules are then dry screened with the help of a Comil screen machine,
- the screened granules are filled into a suitable free-fall blender, e.g. a container mixer, croscarmellose sodium (crosslinked carboxymethylcellulose sodium) and MgStearate are added subsequently, and blended for in sum 10-20 min, preferably 15 minutes at a mixing speed of 10 rpm until homogeneous.
- the granules are dried in the same chamber at an inlet air temperature of approximately 60-90° C.
- Granules are dried when the water activity of the resulting dry granules is below 0.6, while the compression properties of these granules are improved by lower moisture contents.
- the dried granules are then dry-screened using a Comil screening machine.
- the screened granules are filled into a suitable free-fall blender, e.g. a container mixer.
- Croscarmellose sodium crosslinked carboxymethylcellulose sodium
- Magnesium stearate are added either together or subsequently, and blended either together, or subsequently, for in sum 10-60 min, preferably 15 minutes at a mixing speed of 10 rpm until homogeneous.
- the final tableting blend is compressed on a suitable tablet press (e.g. rotary press) to the respective target weight of the required dose strength of compound III tablets using the appropriate tools (e.g. in case of 10 mg tablets: 6 mm round; biconvex; with bevelled edges, or 5.5 mm round; biconvex; with bevelled edges, in case of 25 mg tablets: 8 mm round; biconvex; with bevelled edges or 12 ⁇ 5.9 mm oblong shaped, in case of 50 mg tablets: 14 ⁇ 6.8 mm oblong shaped or 12 ⁇ 5.9 mm oblong shaped).
- Predetermined hardness specifications for the different tool dimensions have to be followed in order to achieve the intended drug dissolution profile and product characteristics. Tablets of all dosages are compressed to result in a tensile strength of approximately 1.5 MPa, this tensile strength is translated into individual hardness specifications for all dosages according to the equations given in the USP/NF.
- a colored film coating has to be applied to the tablet cores in order to achieve a stable and consumer friendly product, especially for product differentiation to prevent from medication errors.
- a coating suspension is prepared by filling purified water into a suitable mixing vessel, and dissolving propyleneglycol and then hydroxypropylmethylcellulose with the help of a propeller or high shear stirrer.
- an aqueous slurry of titanium dioxide, talc, iron oxide yellow and/or iron oxide red if needed (in case of coloured film tablets) is poured and stirred into the film-forming polymer solution.
- the dry matter of this coating suspension is in the range of 10-15%, preferrably about 12-13%.
- the suspension may also be prepared from a ready to use dry mixture that contains the same or chemically comparable components.
- the above prepared tablet cores are filled into a suitable film coater (i.e. with perforated pan and top spray system, alternatively Accela Cota with a 36′′ pan with perforated pan and top spray system is also applicable, less proffered is a pan coater), and preheated up to a temperature of approximately 40-50° C. or above at an inlet air temperature of approximately 60-70° C., preferably at 65° C. After this product temperature is reached the coating suspension is sprayed onto the cores with the help of one or more spray nozzles at a spray pressure of about 1-5 bar depending on nozzle design, production scale and spray rate.
- a suitable film coater i.e. with perforated pan and top spray system, alternatively Accela Cota with a 36′′ pan with perforated pan and top spray system is also applicable, less proffered is a pan coater
- the film-coated tablets may be dried if needed, then cooled down to 40° C. or below, preferably to approx. 30° C. before the equipment is discharged.
- the total process time for the film-coating is in the range of 1-4 hours (depending on the spray rate as well as the batch size), other process durations are also feasible.
- an increased dissolution rate of the active ingredient ( FIG. 5 ) is achieved.
- At least or more than 80% of the drug load is dissolved typically after 45 min, more typically after 30 min, and most typically after 15 min using the paddle method (according to USP/NF and Ph. Eur. apparatus 2 ) dissolution test conditions at 50 rpm and at pH 6.8 (900 mL of 0.05 M Phosphate buffer ( FIG. 5 ).
- Formulation 1 and formulation 2 are both useful pharmaceutical compositions.
- the clinical trial disclosed below was designed to show the efficacy of compound III in improvement of cognitive impairment in patients with schizophrenia as compared to placebo. All patients were on stable antipsychotic treatment (see Table 8 in FIGS. 6A-6C ). The study was a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel group trial.
- Patients eligible for the trial based on the aforementioned criteria were assigned at random in a 2:1:1:1:1 ratio to one of 5 study arms (placebo qd, 10 mg qd, 25 mg qd, 50 mg qd, and 100 mg qd) and followed for 12 weeks of treatment.
- the primary endpoint in this trial is the change from baseline in cognitive function as measured by the Measurement and Treatment research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) composite score after 12 weeks of treatment.
- the key secondary efficacy endpoint is the change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) global ratings after 12 weeks of treatment.
- the primary safety endpoints are as follows:
- the secondary safety endpoint is the change in psychopathology symptoms as assessed by PANSS.
- Stage 1 analysis was performed after 70% of patients complete the 12-week treatment period, and 30% of patients were randomly selected from the 70% of patients for Stage 1 analysis.
- Stage 1 analysis was considered as an internal-pilot study with the objective to explore the Cambridge Neuropsychological Test Automated Battery (CANTAB) endpoints, while Stage 2 was considered as the confirmatory stage to formally test the primary endpoint selected from Stage 1. No adaptation in trial conduct was made, and only the statistical analysis plan was different for the two stages. This report summarizes the results of the Stage 2 analysis.
- CANTAB Cambridge Neuropsychological Test Automated Battery
- the treated set consisted of all patients who were randomised and treated with at least one dose of study drug; this set was used for the analysis of safety results.
- the full analysis set consisted of all randomisation patients who were treated with at least one dose of study drug and had a baseline and at least one post-baseline on-treatment efficacy measurement (MCCB or CANTAB) measurement.
- MCCB or CANTAB post-baseline on-treatment efficacy measurement
- the FAS was used for the primary analyses in both stages. For the Stage 1 analysis, only patients who met the FAS definition were included and from those patients, 120 were randomly selected based on the pre-defined number of patients for each group.
- Stage 2 the primary efficacy endpoint was analysed using the restricted maximum likelihood based mixed effects model with repeated measurements (MMRM) for the change from baseline of the selected CANTAB endpoints after 12 weeks of treatment. Descriptive statistics were used for safety parameters and other efficacy parameters.
- the clinical trial disclosed below is in planning conducted to evaluate the efficacy, safety and tolerability of compound III given as an oral tablet during 52 weeks of treatment of 50 mg, twice daily (BID) compared to placebo in patients meeting diagnostic criteria for attenuated psychosis syndrome as defined in DSM-V.
- BID twice daily
- the study is designed to show superiority of compound III over placebo in preventing first episode of psychosis, as well as improvement in cognition and functional capacity.
- the study is a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel group design.
- Compound III (50 mg) and matching placebo is supplied as film-coated tablets (formulation 2).
- Attenuated Psychosis Syndrome APS
- SIPS Structured Interview for Psychosis-Risk Syndromes
- NAPLS North American Prodromal Longitudinal Study
- Patients eligible for the trial based on the aforementioned criteria may be assigned at random in a 1:1 ratio to one of 2 study arms (placebo bid, and 50 mg bid) and followed for 52 weeks of treatment.
- the primary endpoint is time to first episode of psychosis within a 52 week timeframe.
- First episode of psychosis defined as:
- a new prescription or increase in dose of an ongoing antipsychotic medication for worsening of psychosis symptoms A new prescription or increase in dose of an ongoing antipsychotic medication for worsening of psychosis symptoms.
- Time of onset of first episode psychosis is defined using the rater's best estimate as recorded in the Scale of Prodromal Symptoms (SOPS) interview or when the patient began taking a new prescription or increased the dose of antipsychotic medication.
- SOPS Scale of Prodromal Symptoms
- the primary safety endpoints are as follows:
- the secondary safety endpoint is the change in psychopathology symptoms as assessed by PANSS.
- the equality of the hazard rates will be tested by the Wald test for the treatment effect in a stratified Cox proportional hazards model at the two-sided 10% significance level.
- the model includes the treatment effect as the only covariate and is stratified by NAPLS risk calculator score and baseline use of antipsychotics. Secondary change from baseline endpoints will be analyzed using the restricted maximum likelihood (REML) based mixed effects model with repeated measurements (MMRM).
- REML restricted maximum likelihood
- MMRM mixed effects model with repeated measurements
Abstract
The present invention relates to compound III
and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
Description
- The present invention relates to compound III for the use in the treatment of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases like first episode of psychosis (FEP), relapses of these diseases like reduction of relapse in patients with schizophrenia (REX), polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
- Schizophrenia spectrum and other psychotic disorders include schizophrenia, psychosis, other psychotic disorders, and schizotypal (personality) disorder. Furthermore they include delusional disorder, attenuated psychosis syndrome, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, other specified schizophrenia spectrum and other psychotic disorder, unspecified schizophrenia spectrum and other psychotic disorder, catatonia associated with another mental disorder (catatonia specifier), and catatonic disorder due to another medical condition.
- They are defined by clusters of symptoms including delusions, hallucinations, disorganized thinking (speech), grossly disorganized or abnormal motor behavior (including catatonia), suicidal ideation, or negative symptoms (i.e. diminished emotional expression or avolition) such as anhedonia and social withdrawal. Suicidal behavior is sometimes in response to command hallucinations to harm oneself or others.
- A first episode of psychosis is the first time a person experiences a psychotic episode.
- Schizophrenia is a chronic, severe, and disabling brain disorder affecting about one percent of the world's general population. Schizophrenia affects men and women equally. It occurs at similar rates in all ethnic groups around the world. Despite advances in the treatment of schizophrenia over the past decades, the illness continues to be associated with poor outcomes. These poor outcomes are in part due to identification and intervention late in the course of the illness, thus making it more challenging to reverse.
- In the Global Burden of Disease 2000 study, published in the World Health Report 2001, schizophrenia is the 7th leading cause of years lived with disability (YLDs) at global level, accounting for 2.8% of total global YLDs. Further the Disability Adjusted Life Years (DALYs), reflecting the sum of years of potential life lost due to premature mortality and the years of productive life lost due to disability is estimated at 15.6 million. In the Global Burden of Disease Study 2010”, 1100 sequelae of over 220 diseases were studied: the health state with the highest disability weight was acute schizophrenia (Salomon J A, Vos T, Hogan D, Gagnon M, Naghavi M, Mokdad A, et al. Lancet 2012; 380 (9859):2129-2143).
- Due in part to the recognition of the terrible burden of established disease, the emphasis in therapy is now shifting to defining psychosis-risk syndromes and evaluating treatments that can prevent transition to psychosis in these ultra-high risk groups in addition to prompt intervention when psychosis occurs. Before the occurrence of a first episode of psychosis, those at risk for such an event also demonstrate similar symptoms at a reduced or attenuated degree and are now categorized within DSM-V as demonstrating “attenuated psychosis syndrome”. A first episode is a first manifestation of the disorder meeting the defining diagnostic symptom criteria.
- In subjects who progress from attenuated psychosis syndrome to their first-episode of schizophrenia, relapse rates after initial stabilization exceed 80% within five years, and the occurrence of relapse itself represents an important predictor of subsequent relapse, tripling healthcare costs in the year following (Ascher-Svanum et al. BMC Psychiatry 2010, 10:2; http://www.biomedcentral.com/1471-244X/10/2). Further, multiple relapses have been associated with poorer long-term outcome (Lieberman, J. A. (1993) Journal of Clinical Psychiatry, 54 (3 SUPPL.), pp. 13-17; Lieberman, J. A., Koreen, A. R., Chakos, M., Sheitman, B., Woerner, M., Alvir, J. Ma. J., Bilder, R. (1996) Journal of Clinical Psychiatry, 57 (SUPPL. 9), pp. 5-9; Andreasen, N.C., Liu, D., Ziebell, S., Vora, A., Ho, B.-C. (2013) American Journal of Psychiatry, 170 (6), pp. 609-615).
- Relapse in schizophrenia is defined as the reoccurrence of previously treated psychotic symptoms and may include hallucinations, delusions, strong and inappropriate emotions, and disordered thought. It is also defined as any of the following: re-hospitalization for psychiatric illness, or emergency room (ER) visits for psychiatric illness, clinical worsening, or clinical worsening as assessed by Positive and Negative Syndrome Scale (PANSS), or worsening suicidal ideation and behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). In the course of the illness most patients with schizophrenia experience multiple relapses which are characterized by acute psychotic exacerbation (DSM-V). Current antipsychotics do not eradicate schizophrenia spectrum, other psychotic disorders or psychotic symptoms in the majority of patients but only dampen them (Kapur S (2003) Am. J. Psychiatry 160:13-23; Kapur S (2004) Trends Pharmacol. Sci. 25:402-406).
- WO 2009/121919 discloses a number of pyrazolopyrimidinones as potent PDE9 inhibitors. Among others, WO 2009/121919 discloses compound III
- Further, WO 2009/121919 generically discloses that the compounds exemplified therein may be used in the treatment of cognitive impairment related to several diseases.
- The objective technical problem underlying the present invention is thus to provide a drug substance
-
- which may be used in the treatment of:
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- which may be used in the treatment of:
- In a clinical study designed to investigate compound III for the treatment of cognitive impairment associated with schizophrenia it was surprisingly found, that all serious adverse events (SAEs, 8/8) defined as psychiatric worsening occurred in the placebo arm (100% of SAEs) versus none in any active arm (see Table 9 In
FIG. 7 ). Compared to placebo, treatment of patients with schizophrenia who are receiving antipsychotic therapy with compound III resulted in statistically significant, clinically meaningful decrease in psychiatric serious adverse events (hospitalization for serious worsening of schizophrenia symptoms) and decrease in the intensity and occurrence of suicidal ideation. - According to the present invention, compound III has surprisingly been found to fulfil the above mentioned criteria required for use in the treatment of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- Furthermore compound III can be used in the treatment of first episodes of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- Furthermore compound III can be used in the treatment of relapses of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- Furthermore compound III can be used in the prevention/delay of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- Furthermore compound III can be used in the prevention/delay of first episodes and/or relapses of above mentioned diseases, conditions and symptoms.
- Furthermore compound III can be used in the treatment of schizophrenia by disease stabilization, schizophrenia by reducing the severity of relapses, schizophrenia by prevention of relapses, or schizophrenia by delaying relapses.
- Furthermore compound III can be used in the treatment of symptoms of above mentioned diseases, conditions and symptoms.
- Accordingly compound III can be used in the treatment of:
-
- delusions,
- hallucinations,
- disorganized thinking (speech),
- grossly disorganized or abnormal motor behavior (including catatonia),
- suicidal ideation, or
- negative symptoms.
- Furthermore compound III can be used in the prevention/delay of first episodes and/or relapses of above mentioned symptoms.
-
FIG. 1 shows the X-ray powder diffraction pattern of Compound IIIa. -
FIG. 2 shows the X-ray powder diffraction pattern of Compound IIIb. -
FIG. 3 shows the Raman spectrum of Compound IIIa. -
FIG. 4 shows the Raman spectrum of Compound IIIb. -
FIG. 5 shows the dissolution profiles of core tablets and film-coated tablets containing 50 mg of Formulation 2 (Table 5 and Table 6) produced from milled drug substance. -
FIGS. 6A-6C (Table 8) include data showing the results of a study using antipsychotic drugs for concomitant antipsychotic therapy. -
FIG. 7 includes data showing the Frequency [N (%)] of subjects with serious adverse events by treatment, primary system organ class and preferred term—treated set (TS). - According to a first aspect, the present invention provides compound III:
- for use in the treatment of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- According to a second aspect, the present invention provides compound III for use in the treatment of first episodes of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- According to another aspect, the present invention provides compound III for use in the treatment of relapses of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- According to another aspect, the present invention provides compound III for use in the prevention/delay of:
-
- Schizophrenia spectrum and other psychotic disorders,
- Schizophrenia,
- Psychosis,
- Schizotypal (personality) disorder,
- Delusional disorder,
- Attenuated psychosis syndrome,
- Brief psychotic disorder,
- Schizophreniform disorder,
- Schizoaffective disorder,
- Substance/Medication-Induced Psychotic Disorder,
- Psychotic Disorder Due to Another Medical Condition,
- Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
- Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
- Catatonia Associated With Another Mental Disorder, or
- Catatonic Disorder Due to Another Medical Condition.
- According to another aspect, the present invention provides compound III for use in the prevention/delay of first episodes and/or relapses of above mentioned diseases, conditions and symptoms.
- According to another aspect, the present invention provides compound III for use in the treatment of schizophrenia by disease stabilization, schizophrenia by reducing the severity of relapses, schizophrenia by prevention of relapses, or schizophrenia by delaying relapses.
- According to another aspect, the present invention provides compound III for use in the treatment of reduction of relapse in schizophrenia.
- According to another aspect, the present invention provides compound III for use in the treatment of reduction of relapse in patients with schizophrenia receiving antipsychotic therapy.
- According to another aspect, the present invention provides compound III for use in the treatment of attenuated psychosis syndrome.
- According to another aspect, the present invention provides compound III for use in the prevention of first episode psychosis.
- According to another aspect, the present invention provides compound III for use in the prevention of first episode psychosis in individuals with attenuated psychosis syndrome.
- According to another aspect, the present invention provides compound III for use in the treatment of symptoms of above mentioned diseases, conditions and symptoms.
- According to another aspect, the present invention provides compound III for use in the treatment of:
-
- delusions,
- hallucinations,
- disorganized thinking (speech),
- grossly disorganized or abnormal motor behavior (including catatonia),
- suicidal ideation, or
- negative symptoms.
- According to another aspect, the present invention provides compound III for use in the treatment of first episodes and/or relapses of above mentioned symptoms.
- According to another aspect, the present invention provides compound III for use in the prevention/delay of first episodes and/or relapses of above mentioned symptoms.
- According to another aspect, the present invention provides compound III according to any one of the preceding aspects, characterized in that compound III is administered in addition to treatment with another antipsychotic drug.
- According to another aspect, the present invention provides compound III according to any one of the preceding aspects, characterized in that the antipsychotic drug is selected from the group consisting of Aripiprazole, Risperidone, Quetiapine fumarate, Olanzapine, Paliperidone, Lurasidone hydrochloride, Haloperidol, Paliperidone palmitate, Ziprasidone hydrochloride, Quetiapine, Ziprasidone, Blonanserin, Chlorpromazine hydrochloride, Amisulpride, Haloperidol decanoate, Lithium carbonate, Asenapine maleate, Sulpiride, Chlorpromazine, Flupentixol, Fluphenazine decanoate, Flupentixol decanoate, Fluphenazine, Fluphenazine hydrochloride, Iloperidone, Levomepromazine, Levosulpiride, Loxapine, Lurasidone, Periciazine, Perospirone hydrochloride, Perphenazine, Clozapine, and Pipamperone hydrochloride.
- According to another aspect, the present invention provides compound III according to any one of the preceding aspects, characterized in that 10, 25, 50 or 100 mg of compound III are administered.
- According to another aspect, the present invention provides compound III according to any one of the preceding aspects, characterized in that compound III is administered once or twice daily.
- According to another aspect, the present invention provides compound III according to any one of the preceding aspects, characterized in that compound III is administered orally.
- WO 2009/121919 discloses the synthesis of compound IIIa. Now, it has surprisingly been found that another polymorphic form, compound IIIb, exists. Both compound IIIa and compound IIIb, respectively, can be synthesized in pure form. Compound IIIa was obtained in a purity >95% (ratio between compound IIIa and compound IIIb >95:5 based on XRPD) as well as compound IIIb in a purity >95% (ratio between compound IIIb and compound IIIa >95:5 based on XRPD). Further, both compound IIIa and compound IIIb are characterized by its corresponding XRPD and Raman data.
- As used herein, the term “compound IIIa” refers to crystalline form a of Compound III.
- As used herein, the term “compound IIIb” refers to crystalline form b of Compound III.
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at the following 2-theta values measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 7.7°±0.2° and 9.0°±0.2°.
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at any one or all of the following 2-theta values measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 17.3°±0.2°, 21.3°±0.2°, 20.9°±0.2°, 23.3°±0.2°, 9.0°±0.2°, 14.7°±0.2°, 7.7°±0.2°.
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, shows a X-ray powder diffraction pattern comprising peaks at the following 2-theta values measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 7.7°±0.2° and 9.0°±0.2°, and the Raman spectrum comprises peaks at any one or all of the following Raman shifts expressed in wavenumbers in cm−1: 1190±2, 1401±2, 1675±2.
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >75% (ratio between compound IIIa and compound IIIb >75:25 based on XRPD).
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >90% (ratio between compound IIIa and compound IIIb >90:10 based on XRPD).
- The polymorphic form resulting from the synthesis according to WO 2009/121919, namely compound IIIa, has a purity >95% (ratio between compound IIIa and compound IIIb >95:5 based on XRPD).
- According to another aspect, the present invention provides compound IIIb showing a X-ray powder diffraction pattern comprising a peak at the following 2-theta value measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 6.4°±0.2°.
- According to another aspect, the present invention provides compound IIIb showing a X-ray powder diffraction pattern comprising peaks at any one or all of the following 2-theta values measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 20.8°±0.2°, 21.1°±0.2°, 21.6°±0.2°, 6.4°±0.2°, 23.0°±0.2°, 25.2°±0.2°, 12.9°±0.2°.
- According to another aspect, the present invention provides compound IIIb showing a X-ray powder diffraction pattern comprising peaks at the following 2-theta values measured using monochromatic CuKα1 radiation of λ=1.54056 Å, 40 kV, 40 mA: 6.4°±0.2°, and the Raman spectrum comprises peaks at any one or all of the following Raman shifts expressed in wavenumbers in cm−1: 1182±2, 1394±2, 1663±2.
- According to another aspect, the present invention provides compound IIIb having a purity >10% (ratio between compound IIIb and compound IIIa >10:90 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >20% (ratio between compound IIIb and compound IIIa >20:80 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >30% (ratio between compound IIIb and compound IIIa >30:70 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >40% (ratio between compound IIIb and compound IIIa >40:60 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >50% (ratio between compound IIIb and compound IIIa >50:50 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >60% (ratio between compound IIIb and compound IIIa >60:40 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >70% (ratio between compound IIIb and compound IIIa >70:30 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >75% (ratio between compound IIIb and compound IIIa >75:25 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >80% (ratio between compound IIIb and compound IIIa >80:20 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >90% (ratio between compound IIIb and compound IIIa >90:10 based on XRPD).
- According to another aspect, the present invention provides compound IIIb having a purity >95% (ratio between compound IIIb and compound IIIa >95:5 based on XRPD).
- In another aspect, the present invention relates to compound III, compound IIIa, compound IIIb or mixtures thereof for use in the treatment of above mentioned diseases, conditions and symptoms.
- Further, it has surprisingly been found that by combining hydroxypropyl cellulose and/or croscarmellose sodium with compound III, IIIa or IIIb or a mixture thereof in a pharmaceutic composition the drug load can be adjusted to the same level for all dose strengths and a fast dissolution of the tablet can be reached irrespective of the low intrinsic dissolution rate of compound III in the physiologically relevant pH range above pH 4 (
formulation 1, Table 3, and/orformulation 2, Table 5,FIG. 5 ). - Another aspect of the present invention relates to the pharmaceutical composition comprising compound III, IIIa or IIIb or a mixture thereof and hydroxypropyl cellulose and/or croscarmellose sodium.
- According to another aspect, the present invention relates to the pharmaceutical composition comprising corn starch and hydroxypropyl cellulose and/or croscarmellose sodium.
- According to another aspect, the present invention relates to the pharmaceutical composition comprising lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and pregelatinized starch or corn starch.
- According to another aspect, the present invention relates to a pharmaceutical composition comprising a tablet core consisting of compound III, lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and pregelatinized starch or corn starch.
- According to another aspect, the present invention relates to a pharmaceutical composition comprising a tablet core consisting of 1-30% (wt/wt) compound III, 63-83% (wt/wt) lactose monohydrate, 5-25% (wt/wt) pregelatinized starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- According to another aspect, the present invention relates to a pharmaceutical composition comprising a tablet core consisting of 8-24% (wt/wt) compound III, 53-70% (wt/wt) lactose monohydrate, 10-20% (wt/wt) pregelatinized starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- According to another aspect, the present invention relates to a pharmaceutical composition comprising a tablet core consisting of 1-30% (wt/wt) compound III, 50-80% (wt/wt) lactose monohydrate, 5-20% (wt/wt) corn starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- According to another aspect, the present invention relates to a pharmaceutical composition comprising a tablet core consisting of 8-24% (wt/wt) compound III, 65-75% (wt/wt) lactose monohydrate, 5-20% (wt/wt) corn starch, 1-3% (wt/wt) hydroxypropyl cellulose, 1-5% (wt/wt) croscarmellose sodium, and 0.5-3.5% (wt/wt) magnesium stearate.
- Another aspect of the present invention relates to a pharmaceutical composition as defined above for use in the above mentioned diseases, conditions and symptoms.
- Another aspect of the present invention relates to a method of treatment of above mentioned diseases, conditions and symptoms.
- Terms not specifically defined herein should be given the meanings that would be given to them by one skilled in the art in light of the disclosure and the context.
- If not otherwise specified, the term compound III relates to the compound of the following structure
- in any polymorphic form or mixtures or pharmaceutically acceptable salts or hydrates thereof.
- The term “Subject” means a human patient.
- The term “adverse event (AE)” means any untoward medical occurrence, including an exacerbation of a pre-existing condition, in a patient in a clinical investigation who received a pharmaceutical product. The event did not necessarily have to have a causal relationship with this treatment.
- The term “adverse event (SAE)” means any AE which resulted in death, was immediately life-threatening, resulted in persistent or significant disability/incapacity, required or prolonged patient hospitalisation, was a congenital anomaly/birth defect, or was to be deemed serious for any other reason if it was an important medical event when based upon appropriate medical judgement which might jeopardise the patient and might require medical or surgical intervention to prevent one of the other outcomes listed in the above definitions.
- BID bis in die (twice daily dosing)
ER emergency room
ESI electrospray ionization - HCl hydrochloric acid
HPMC hypromellose=hydroxypropylmethylcellulose
HR high-resolution
IDR intrinsic dissolution rate=intrinsic solubility
i.v. intravenous
M mole, mol/L - ml milliliter
MS mass spectrometry
m/z mass-to-charge ratio
NMR nuclear magnetic resonance
PDE phosphodiesterase
qd quaque die (once a day)
rpm revolutions per minute
RT room temperature - wt weight
XRPD X-ray powder diffraction -
-
Instrument QTOF HDMS Synapt (Micromass, Manchester, UK) Instrument control software Masslynx 4.1 Ion source ESI+ (Lockspray source) Lockspray/DXC on/off Calibration sodium formate, Leu-Enkephalin lockmass calibration Resolution MS1(LM/HM) 4.7/15 Resolving power (FWHM) 14935 at m/z 312 (W mode) MCP voltage 1700 V Capillary voltage +3.0 kV Cone voltage 8 V Collision energy 2 eV Collision gas Argon Source temperature 120° C. Desolvation temperature 200° C. Cone gas nitrogen 48 L/h Desolvation gas nitrogen 600 L/h Sample inlet Via UPLC (Waters Acquity System) Spray solvent flow rate 300 μl/min Sample concentration 0.5 mg/ml in acetonitrile/water (1:1/v:v), 0.5 μl injected Reagents 0.1% formic acid in acetonitrile (ULC/MS, Biosolve) 0.1% formic acid in water (ULC/MS, Biosolve) Scan range 50-1000 u Scan time 0.16 s No. of scans combined 15 Data threshold 2.0% -
-
Instrument Bruker Avance III 600 NMR spectrometer Frequency 600.38 MHz Software Bruker TopSpin ® version 3.0 Pulse program zg30 Solvent DMSO-d6, Sigma Aldrich, Batch MKBT4612V Concentration 15.3 mg/0.6 ml Temperature 27° C. Calibration Tetramethylsilane (≡TMS: δ = 0.00 ppm) Sweep width 12315 Hz Size 64K data points Pulse width 30 degree Relaxation delay 2 s Number of scans 64 Dummy scans 2 Apodization zerofilling to 128K data points exponential multiplication (LB: 1.00 Hz) -
-
Instrument Bruker Avance III 600 NMR spectrometer Frequency 150.98 MHz Software Bruker TopSpin ® version 3.0 Pulse program zgpg30 Solvent DMSO-d6, Sigma Aldrich, Batch MKBT4612V Concentration 15.3 mg/0.6 ml Temperature 27° C. Calibration Unified scale (IUPAC Recommendations 2001) Sweep width 37879 Hz Size 64K data points Pulse width 30 degree Relaxation delay 10 s Number of scans 3072 Dummy scans 4 Apodization zerofilling to 128K data points Exponential multiplication (LB: 1.00 Hz) - X-ray powder diagrams were generated using a STOE—STADI P-diffractometer in transmission mode fitted with a MYTHEN-detector and a Cu-anode as X-ray source with monochromatic CuKα1 radiation (λ=1.54056 Å, 40 kV, 40 mA). The standard error range for the 2-theta values is ±0.2°.
- Kaiser Optics RXN2 dispersive Raman PhAT Probe with 6 mm optics, laser power 400 mW,
Exposure time 1 sec. The spectral resolution is 4 cm−1. -
- 5-Amino-1H-pyrazole-4-carboxylic acid amide I (64.0 kg, 304.4 mol) and 2-pyridineacetic acid methyl ester II (69.1 kg, 457.1 mol) are suspended in tert.-Amyl alcohol (84 kg) and heated to 80-90° C. A solution of potassium tert.-amylate (25% in toluene, 230.6 kg, 457.1 mol) is added at 80-90° C. The dropping funnel is rinsed with toluene (84 kg). The reaction mixture is heated to reflux. After complete conversion the mixture is cooled down to 55-65° C. and water (192 kg) is added to the reaction mixture.
- After phase separation ethanol (38.0 kg) and acetic acid (11.0 kg) is added to the aqueous phase at 55-65° C. A second portion of acetic acid (11.0 kg) is added at 55-65° C. The dropping funnel is rinsed with ethanol (25 kg) and the reaction mixture is cooled to 15-25° C. The suspension is filtered and the filter cake washed with water (256 kg). The isolated material is dried at max. 60° C. to give Compound IIIa (crude, form a) (75.8-85.3 kg, 80-90%).
- Optionally, crystallization can be initiated by seeding with compound IIIa prior to addition of the second portion acetic acid.
- NMR (1H, 600 MHz, DMSO-d6): 12.26 (1H, s), 8.48 (1H, br. d), 8.05 (1H, s), 7.77 (1H, tb), 7.41 (1H, d), 7.28 (1H, dd), 4.75 (1H, m), 4.20 (2H, s), 3.94 (2H, m), 3.49 (2H, m), 2.09 (2H, m), 1.80 (2H, m).
- NMR (13C, 150 MHz, DMSO-d6): 158.4, 158.3, 156.7, 152.0, 149.6, 137.4, 134.5, 124.0, 122.6, 104.7, 66.4, 53.3, 43.3, 32.4.
- HRMS (ESI): m/z 312 ([M+H]+; 312.1465).
- See Table 1 and
FIG. 1 for characterizing data. -
- 5-Amino-1H-pyrazole-4-carboxylic acid amide I (50.0 kg, 237.8 mol) and 2-pyridineacetic acid methyl ester II (53.9 kg, 356.6 mol) are suspended in tert.-Amyl alcohol (65.6 kg) and heated to 80-90° C. A solution of potassium tert.-amylate (25% in toluene, 180.2 kg, 356.6 mol) is added at 80-90° C. The dropping funnel is rinsed with toluene (43.5 kg). The reaction mixture is heated to reflux. After complete conversion the mixture is cooled down to 55-65° C. and water (150 kg) is added to the reaction mixture. The mixture is cooled down to 15-25° C. After phase separation ethanol (23.7 kg) and acetic acid (17.2 kg) is added to the aqueous phase at 15-30° C. The suspension is stirred for 60 min at 15-25° C. The suspension is filtered and the filter cake washed with water (200 kg). The isolated material is dried at max. 60° C. to give Compound IIIb (crude, form b) (51.8-59.2 kg, 70-80%).
- NMR (1H, 600 MHz, DMSO-d6): 12.26 (1H, s), 8.48 (1H, br. d), 8.05 (1H, s), 7.77 (1H, tb), 7.41 (1H, d), 7.28 (1H, dd), 4.75 (1H, m), 4.20 (2H, s), 3.94 (2H, m), 3.49 (2H, m), 2.09 (2H, m), 1.80 (2H, m).
- NMR (13C, 150 MHz, DMSO-d6): 158.4, 158.3, 156.7, 152.0, 149.6, 137.4, 134.5, 124.0, 122.6, 104.7, 66.4, 53.3, 43.3, 32.4.
- HRMS (ESI): m/z 312 ([M+H]+; 312.1465).
- See Table 2 and
FIG. 2 for characterizing data. -
- Compound IIIa or IIIb (crude, form a or form b) (44.5 kg, 142.9 mol) is suspended in ethanol (474 kg) and water (13.4 kg). The mixture is heated to reflux and stirred for 45 min. The solution is cooled to 72-78° C. and polish filtered. The filter is rinsed with ethanol (54 kg). The mixture is cooled to 58-65° C. Optionally, crystallization can be initiated by seeding with compound IIIa (form a) after cooling to 58-65° C. The mixture is cooled to 0-10° C. The suspension is filtered and the filter cake washed with ethanol (70 kg). The isolated material is dried at max. 60° C. to give Compound IIIa (unmilled, form a) (37.8-42.3 kg, 85-95%).
- NMR (1H, 600 MHz, DMSO-d6): 12.26 (1H, s), 8.48 (1H, br. d), 8.05 (1H, s), 7.77 (1H, tb), 7.41 (1H, d), 7.28 (1H, dd), 4.75 (1H, m), 4.20 (2H, s), 3.94 (2H, m), 3.49 (2H, m), 2.09 (2H, m), 1.80 (2H, m).
- NMR (13C, 150 MHz, DMSO-d6): 158.4, 158.3, 156.7, 152.0, 149.6, 137.4, 134.5, 124.0, 122.6, 104.7, 66.4, 53.3, 43.3, 32.4.
- HRMS (ESI): m/z 312 ([M+H]+; 312.1465).
- See Table 1 and
FIG. 1 for characterizing data. -
- Compound IIIa or IIIb (crude, form a or form b) (2.2 kg, 7.1 mol) is suspended in ethanol (4.4 L) and water (7.7 L) at room temperature. Aqueous sodium hydroxide (45%, 691 g, 7.7 mol) is added via a pump keeping the internal temperature at 15-25° C. The pump is rinsed with water (1.1 L) and the reaction mixture stirred at room temperature for 35 min. Acetic acid (515 g, 8.4 mol) is added via a pump keeping the internal temperature at 15-25° C. The pump is rinsed with ethanol (1.1 L) and the reaction mixture stirred at room temperature for 75 min. The suspension is filtered and the filter cake washed with water (8.8 kg). The isolated material is dried at max. 60° C. to give Compound IIIb (unmilled, form b) (2.0 kg, 92%).
- NMR (1H, 600 MHz, DMSO-d6): 12.26 (1H, s), 8.48 (1H, br. d), 8.05 (1H, s), 7.77 (1H, tb), 7.41 (1H, d), 7.28 (1H, dd), 4.75 (1H, m), 4.20 (2H, s), 3.94 (2H, m), 3.49 (2H, m), 2.09 (2H, m), 1.80 (2H, m).
- NMR (13C, 150 MHz, DMSO-d6): 158.4, 158.3, 156.7, 152.0, 149.6, 137.4, 134.5, 124.0, 122.6, 104.7, 66.4, 53.3, 43.3, 32.4.
- HRMS (ESI): m/z 312 ([M+H]+; 312.1465).
- See Table 2 and
FIG. 2 for characterizing data. - The micronization was performed using the pilot plant opposed jet mill 140 AFG (Hosokawa-Alpine AG, Augsburg) applying the following process parameters for Compound IIIa (unmilled, form a):
-
Milling Classifier Dosage Injector Pressure [bar] Speed [rpm] [kg/h] pressure [bar] 5.0 3500 15.0 1 - A particle size distribution in terms of x90<28 μm was achieved. For analysis laser diffraction/dry dispersion Sympatec was used.
- Solid state properties of Compound III crude (form a or b) and Compound III unmilled (form a or b), respectively
- Appearance In the solid state, the Compounds IIIa and IIIb are white microcrystalline materials.
- Compound IIIa is highly crystalline as can be seen in the X-ray powder diffraction diagram in
FIG. 1 and RAMAN spectrum inFIG. 3 . - The X-ray powder reflection and intensities (standardised) are shown in Table 1.
-
TABLE 1 intensity I/I0 2 Θ [°] d-value [Å] [%] 7.66 11.54 28 8.96 9.86 52 10.39 8.50 34 13.06 6.78 13 14.27 6.20 6 14.70 6.02 38 15.22 5.82 12 15.35 5.77 6 16.40 5.40 6 17.33 5.11 100 17.89 4.95 43 18.89 4.70 17 19.14 4.63 28 19.50 4.54 6 20.26 4.38 6 20.89 4.25 63 21.25 4.18 76 22.33 3.98 7 22.85 3.89 53 23.31 3.81 62 23.75 3.74 37 24.05 3.70 14 24.97 3.56 45 25.97 3.43 10 26.30 3.39 8 26.44 3.37 8 26.95 3.31 23 27.09 3.29 25 27.35 3.26 10 28.04 3.18 6 - In Table 1 above the value “2-theta [0]” denotes the angle of diffraction in degrees and the d-value [Å] denotes the specified distances in A between the lattice planes.
- The crystalline Compound IIIa is characterised in that in the x-ray powder diagram has, inter alia, the characteristic values 2-theta=17.3°±0.2° (100% relative intensity), 21.3°±0.2° (76% relative intensity), 20.9°±0.2° (63% relative intensity), 23.3°±0.2° (62% relative intensity), 22.9°±0.2° (53% relative intensity), 9.0°±0.2° (52% relative intensity), 25.0°±0.2° (45% relative intensity), 17.9°±0.2° (43% relative intensity), 14.7°±0.2° (38% relative intensity), 23.8°±0.2° (37% relative intensity), 10.4°±0.2° (34% relative intensity), 7.7°±0.2° (28% relative intensity), 19.1°±0.2° (28% relative intensity), 27.1°±0.2° (25% relative intensity), 27.0°±0.2° (23% relative intensity) (most prominent peaks in the diagram of
FIG. 1 , Table 1). - Compound IIIa is characterised in that in the x-ray powder diagram has strong unique reflections at the values 2-theta=7.7°±0.2°, 9.0°±0.2°.
- The ratio of a mixture containing compound IIIa (crude, form a) and a certain amount of compound IIIb (crude, form b) did not change after storage under ambient conditions for 28 months.
- RAMAN spectrum (characteristic bands) [cm−1]: 1190±2, 1401±2 and 1675±2.
- Compound IIIb is highly crystalline as can be seen in the X-ray powder diffraction diagram in
FIG. 2 and RAMAN spectrum inFIG. 4 . - The X-ray powder reflection and intensities (standardised) are shown in Table 2.
-
TABLE 2 intensity I/I0 2 Θ [°] d-value [Å] [%] 6.38 13.84 60 10.36 8.53 41 11.45 7.72 6 12.85 6.88 41 14.71 6.02 5 15.40 5.75 11 15.66 5.66 21 17.65 5.02 61 18.35 4.83 52 19.22 4.61 11 20.81 4.26 100 21.08 4.21 99 21.64 4.10 76 22.46 3.96 29 22.54 3.94 24 23.03 3.86 57 24.05 3.70 14 25.21 3.53 45 25.73 3.46 9 25.87 3.44 7 26.67 3.34 25 27.20 3.28 27 27.83 3.20 4 29.38 3.04 14 29.53 3.02 20 30.24 2.95 9 - In Table 2 above the value “2-theta [0]” denotes the angle of diffraction in degrees and the d-value [Å] denotes the specified distances in A between the lattice planes.
- Compound IIIb is characterised in that in the x-ray powder diagram has, inter alia, the characteristic values 2-theta=20.8°±0.2° (100% relative intensity), 21.1°±0.2° (99% relative intensity), 21.6°±0.2° (76% relative intensity), 6.4°±0.2° (60% relative intensity), 23.0°±0.2° (57% relative intensity), 25.2°±0.2° (45% relative intensity), 10.4°±0.2° (41% relative intensity), 12.9°±0.2° (41% relative intensity), 22.5°±0.2° (29% relative intensity), 27.2°±0.2° (27% relative intensity), 26.7°±0.2° (25% relative intensity) (most prominent peaks in the diagram of
FIG. 2 , Table 2). - Compound IIIb is characterised in that in the x-ray powder diagram has a strong unique reflection at the value 2-theta=6.4°±0.2°.
- RAMAN spectrum (characteristic bands) [cm−1]: 1182±2, 1394±2 and 1663±2.
- The pharmaceutical composition according to the invention is a tablet for oral administration comprising a core, containing compound III, IIIa or IIIb or a mixture thereof and hydroxypropyl cellulose and/or croscarmellose sodium, and further comprising a film coating, enveloping said core.
-
-
TABLE 3 Composition of tablet core formulation 1Dose strength 10 mg 25 mg 50 mg Drug load (%, wt/wt) 16 8 16 Ingredient [mg/tab] [mg/tab] [mg/tab] compound III (Jet milled) 10.000 25.000 50.000 Lactose monohydrate 36.875 209.375 184.375 Pregelatinized starch 12.500 62.500 62.500 Hydroxypropyl cellulose 1.250 6.250 6.250 Croscarmellose sodium 1.250 6.250 6.250 Magnesium stearate 0.625 3.125 3.125 Sub-total: Core tablet 62.500 312.500 312.500 -
TABLE 4 Composition of film coated tablets formulation 1Dose strength 10 mg 25 mg 50 mg [mg/tab] [mg/tab] [mg/tab] Core tablet 62.500 312.500 312.500 Film-coat* 2.500 7.500 7.500 Total Film-coated tablet 65.000 320.000 320.000 *Based on the intended color, the film coat consists of different, and commonly used amounts of hypromellose, propylene glycol, talc, titanium dioxide, and iron oxides. -
-
TABLE 5 Composition of tablet core of formulation 2Dose strength 10 mg 25 mg 50 mg all Drug load (%, wt/wt) 11.76 11.76 11.76 11.76 Ingredient [mg/tab] [mg/tab] [mg/tab] [%, wt/wt] compound III (Jet milled) 10.000 25.000 50.000 11.76 Lactose monohydrate 62.250 155.625 311.250 73.24 Corn starch 8.500 21.250 42.500 10.00 Hydroxypropyl cellulose 1.700 4.250 8.500 2.00 Croscarmellose sodium 1.700 4.250 8.500 2.00 Magnesium stearate 0.850 2.125 4.250 1.00 Sub-total Core 85.000 212.5 425.000 100.00 -
TABLE 6 Composition of film coated tablets formulation 2Dose strength 10 mg 25 mg 50 mg [mg/tab] [mg/tab] [mg/tab] Core tablet 85.000 212.5 425.000 Film-coat* 3.000 5.500 9.000 Total Film coated tablet 88.000 218.000 434.000 *Based on the intended color, the film coat consists of different, and commonly used amounts of hypromellose, propylene glycol, talc, titanium dioxide, and iron oxides. - As one example for the fast and complete dissolution characteristics of the formulations described, the dissolution profiles of core tablets and film-coated
tablets 50 mg (compare Table 5 and Table 6) are shown inFIG. 5 . - A pharmaceutical composition comprising compound III, IIIa or IIIb or a mixture thereof in combination with hydroxypropyl cellulose and/or croscarmellose sodium leads to adjustment of the drug load to the same level for all dose strengths, and a fast dissolution of the tablet can be reached irrespective of the low intrinsic dissolution rate of compound III in the physiologically relevant pH range above
pH 4. - This results in a more flexible usage of the granules, as they can be compressed to all dose strengths at adequate tablet size and tablet weight. A coloured film coat can be added that allows differentiation of the different dosage strengths.
-
Formulation 1 andformulation 2 can be obtained by using either compound IIIa or compound IIIb or mixtures thereof, respectively. -
-
TABLE 7 Description of needed excipient grades Particular preferred grade/type (in addition to pharmacopoeial Ingredient USP/NF, Ph. Eur., JP specification) Lactose monohydrate crystalline, fine Corn starch no additional specification Pregelatinized starch no additional specification Hydroxypropyl cellulose no additional specification Croscarmellose sodium no additional specification Magnesium stearate Specific surface area about 2-10 m2/g - The following equipment was used in the process of preparing the pharmaceutical composition according to the invention.
- The
formulation 1 is preferably produced using the following equipment: -
- Mixing vessel with propeller mixer for granulation liquid;
- High shear mixer/granulator (e.g. different scales of Glatt VG or Diosna type)+Wet screen machine (e.g. Alexanderwerk)+Fluid-bed dryer (e.g. different scales of Glatt GPCG or Glatt WSG type);
- Dry screen machine (e.g. Quadro Comil);
- Free fall blender (e.g. Servolift or container mixer); single punch or Rotary tablet press (e.g. from supplier Fette, or Korsch, or Kilian);
- Mixing vessel with propeller mixer and/or homogenizer for film coating suspension;
- Film coater (i.e. film coater with perforated coating drum)
- The
formulation 2 is preferably produced using the following equipment: -
- Mixing vessel with propeller mixer for granulation liquid;
- Fluidized-bed granulator/dryer (e.g. different scales of Glatt GPCG or Glatt WSG type)
- Dry screen machine (e.g. Quadro Comil);
- Free fall blender (e.g. Servolift or container mixer); single punch or Rotary tablet press (e.g. from supplier Fette, or Korsch, or Kilian);
- Mixing vessel with propeller mixer and/or homogenizer for film coating suspension;
- Film coater (i.e. film coater with perforated coating drum)
- As a first step the granulation liquid for the wet granulation process is prepared. Purified water of about 10-90° C. is filled into a suitable mixing vessel. Then a binding agent such as hydroxypropyl cellulose or hypromellose is stirred in, and the dispersion is cooled down if necessary to room temperature. If necessary, the liquid is allowed to stand overnight (completeness of solution/degassing) and stirred up before use. If necessary, any weight loss is compensated with purified water. The dry matter (solid content) of this granulation liquid is preferrably in the range of 4-7% (wt/wt, assuming feasibility for a range of 2-10%, wt/wt).
- Both
formulations - For high shear granulation the required quantity of compound III active ingredient (depending on the dose strength), lactose monohydrate, corn starch or pregelatinized starch, and mannitol (optionally) are filled in the product bowl of a high-shear mixer/granulator, then mixed homogeneously for about 3-4 min using impeller and chopper blades. Next, the granulation liquid is added either manually or by spray nozzles and the wet mass is granulated for about 2-3 min, again using impeller and chopper blades. After discharging of the high shear mixer/granulator the wet granules are wet-screened through a 3.0 mm mesh size sieve to destroy large agglomerates.
- The wet-screened material is transferred to a conventional fluid bed drier (or alternatively to a tray drier) and dried at an inlet air temperature of approximately 60-90° C. Granules are dried when the water activity of the resulting dry granules is below 0.6. The dried granules are then dry screened with the help of a Comil screen machine, The screened granules are filled into a suitable free-fall blender, e.g. a container mixer, croscarmellose sodium (crosslinked carboxymethylcellulose sodium) and MgStearate are added subsequently, and blended for in sum 10-20 min, preferably 15 minutes at a mixing speed of 10 rpm until homogeneous.
- For the fluidised bed wet granulation process the required quantity of compound III active ingredient (depending on the dose strength and formulation variant), lactose monohydrate, corn starch or pregelatinized starch, and mannitol (optionally) are filled in the product bowl of a fluid-bed granulator, then mixed homogeneously in the chamber of the fluid-bed granulator. Next, the granulation liquid is added by spraying for granulation in the chamber of the fluid-bed granulator at an inlet air temperature of approximately 60-90° C., preferably 75-85° C. until the target amount of granulation liquid is sprayed. After finishing the granulation step, the granules are dried in the same chamber at an inlet air temperature of approximately 60-90° C. Granules are dried when the water activity of the resulting dry granules is below 0.6, while the compression properties of these granules are improved by lower moisture contents. The dried granules are then dry-screened using a Comil screening machine. The screened granules are filled into a suitable free-fall blender, e.g. a container mixer. Croscarmellose sodium (crosslinked carboxymethylcellulose sodium) and Magnesium stearate are added either together or subsequently, and blended either together, or subsequently, for in sum 10-60 min, preferably 15 minutes at a mixing speed of 10 rpm until homogeneous.
- The final tableting blend is compressed on a suitable tablet press (e.g. rotary press) to the respective target weight of the required dose strength of compound III tablets using the appropriate tools (e.g. in case of 10 mg tablets: 6 mm round; biconvex; with bevelled edges, or 5.5 mm round; biconvex; with bevelled edges, in case of 25 mg tablets: 8 mm round; biconvex; with bevelled edges or 12×5.9 mm oblong shaped, in case of 50 mg tablets: 14×6.8 mm oblong shaped or 12×5.9 mm oblong shaped). Predetermined hardness specifications for the different tool dimensions have to be followed in order to achieve the intended drug dissolution profile and product characteristics. Tablets of all dosages are compressed to result in a tensile strength of approximately 1.5 MPa, this tensile strength is translated into individual hardness specifications for all dosages according to the equations given in the USP/NF.
- A colored film coating has to be applied to the tablet cores in order to achieve a stable and consumer friendly product, especially for product differentiation to prevent from medication errors. For this purpose a coating suspension is prepared by filling purified water into a suitable mixing vessel, and dissolving propyleneglycol and then hydroxypropylmethylcellulose with the help of a propeller or high shear stirrer. In a next step an aqueous slurry of titanium dioxide, talc, iron oxide yellow and/or iron oxide red if needed (in case of coloured film tablets) is poured and stirred into the film-forming polymer solution. The dry matter of this coating suspension is in the range of 10-15%, preferrably about 12-13%. The suspension may also be prepared from a ready to use dry mixture that contains the same or chemically comparable components.
- The above prepared tablet cores are filled into a suitable film coater (i.e. with perforated pan and top spray system, alternatively Accela Cota with a 36″ pan with perforated pan and top spray system is also applicable, less proffered is a pan coater), and preheated up to a temperature of approximately 40-50° C. or above at an inlet air temperature of approximately 60-70° C., preferably at 65° C. After this product temperature is reached the coating suspension is sprayed onto the cores with the help of one or more spray nozzles at a spray pressure of about 1-5 bar depending on nozzle design, production scale and spray rate. A spray rate of about 20-600 g/min (depending on the batch size as well as drum speed and other operating conditions) at an inlet air temperature of about 40-80° C., preferably 60° C. It is important to control and maintain the product temperature during spraying at a level of between 40-50° C. to achieve a high quality film-coat. After the spraying is finished the film-coated tablets may be dried if needed, then cooled down to 40° C. or below, preferably to approx. 30° C. before the equipment is discharged. The total process time for the film-coating is in the range of 1-4 hours (depending on the spray rate as well as the batch size), other process durations are also feasible.
- The film-coated tablets of
formulations FIG. 5 ) is achieved. At least or more than 80% of the drug load is dissolved typically after 45 min, more typically after 30 min, and most typically after 15 min using the paddle method (according to USP/NF and Ph. Eur. apparatus 2) dissolution test conditions at 50 rpm and at pH 6.8 (900 mL of 0.05 M Phosphate buffer (FIG. 5 ). - Based on the quality of the tablets produced by the industrial process, the use of compound IIIa for the manufacture of
formulation 2 is preferred. -
Formulation 1 andformulation 2 are both useful pharmaceutical compositions. - Regarding reducing the exacerbations of symptoms characterizing relapse, including suicidality, the clinical trial disclosed below was designed to show the efficacy of compound III in improvement of cognitive impairment in patients with schizophrenia as compared to placebo. All patients were on stable antipsychotic treatment (see Table 8 in
FIGS. 6A-6C ). The study was a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel group trial. - Compound III (10, 25 and 50 mg) and matching placebo were supplied as film-coated tablets (formulation 1).
- In total, 516 patients with schizophrenia on stable antipsychotic treatment (Table 8 in
FIGS. 6A-6C ) as described below were randomized into this trial. - Patients with established diagnoses of schizophrenia (per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) with the following clinical features:
- 1) Clinically stable and are in the residual (non-acute) phase of their illness for at least 8 weeks
- 2) Current antipsychotic and concomitant psychotropic medications must meet the criteria below:
- a) Maintained on current atypical (second generation) antipsychotic medications (in any approved dosage form)
- b) and on current dose for at least 8 weeks prior to randomisation, and/or
- c) Maintained on current typical (first generation) antipsychotic medications and on current dose for at least 6 months, optionally combined with anticholinergics if treated with a stable dose for at least 6 months prior to randomisation, and/or
- d) Maintained on current concomitant psychotropic medications other than anticholinergics, antiepileptics and lithium, and on current dose for at least 8 weeks prior to randomisation. Antiepileptics and lithium are allowed if initiated at least 6 months prior to randomisation.
- 3) Have no more than a “moderate” severity rating on hallucinations and delusions (Positive and Negative Syndrome Scale (PANSS)—positive syndrome Hallucinatory Behavior item score≤4 and Delusions item score ≤4)
- 4) Have no more than a “moderate” severity rating on positive formal thought disorder (PANSS-positive syndrome Conceptual Disorganization item score ≤4)
- 5) Have a minimal level of extrapyramidal symptoms (Simpson-Angus Scale total score <6) and depressive symptoms (PANSS—general psychopathology syndrome Depression item score ≤4)
-
- 1) Patient treated with more than two antipsychotic medications (including more than two dosage forms)
- 2) Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)
- 3) Any suicidal ideation of
type - 4) History or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, haematological or hormonal disorders
- 5) Diseases of the central nervous system (including but not limited to any kind of seizures, stroke or any psychiatric disorders other than schizophrenia)
- Patients eligible for the trial based on the aforementioned criteria were assigned at random in a 2:1:1:1:1 ratio to one of 5 study arms (placebo qd, 10 mg qd, 25 mg qd, 50 mg qd, and 100 mg qd) and followed for 12 weeks of treatment.
- The results of the primary and key secondary efficacy endpoints and the primary and secondary safety endpoints are summarized below.
- The primary endpoint in this trial is the change from baseline in cognitive function as measured by the Measurement and Treatment research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) composite score after 12 weeks of treatment. The key secondary efficacy endpoint is the change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) global ratings after 12 weeks of treatment.
- The primary safety endpoints are as follows:
-
- Occurrence of adverse events (AEs)/serious adverse events (including the abnormalities of physical examination, vital signs, electrocardiogram test and laboratory tests)
- Occurrence of protocol-specified adverse events of special interest
- Dramatic worsening of disease state as assessed by PANSS
- Suicidality as assessed by Columbia Suicidal Severity Rating Scale (C-SSRS)
- The secondary safety endpoint is the change in psychopathology symptoms as assessed by PANSS.
- The statistical analysis was performed in a two-stage fashion.
Stage 1 analysis was performed after 70% of patients complete the 12-week treatment period, and 30% of patients were randomly selected from the 70% of patients forStage 1 analysis.Stage 1 analysis was considered as an internal-pilot study with the objective to explore the Cambridge Neuropsychological Test Automated Battery (CANTAB) endpoints, whileStage 2 was considered as the confirmatory stage to formally test the primary endpoint selected fromStage 1. No adaptation in trial conduct was made, and only the statistical analysis plan was different for the two stages. This report summarizes the results of theStage 2 analysis. - Two analysis sets were used. The treated set (TS) consisted of all patients who were randomised and treated with at least one dose of study drug; this set was used for the analysis of safety results. The full analysis set (FAS) consisted of all randomisation patients who were treated with at least one dose of study drug and had a baseline and at least one post-baseline on-treatment efficacy measurement (MCCB or CANTAB) measurement. The FAS was used for the primary analyses in both stages. For the
Stage 1 analysis, only patients who met the FAS definition were included and from those patients, 120 were randomly selected based on the pre-defined number of patients for each group. - In
Stage 2, the primary efficacy endpoint was analysed using the restricted maximum likelihood based mixed effects model with repeated measurements (MMRM) for the change from baseline of the selected CANTAB endpoints after 12 weeks of treatment. Descriptive statistics were used for safety parameters and other efficacy parameters. - Surprisingly, a striking imbalance in both serious psychiatric adverse events and suicidality were noted in that 8/8 (100%) of psychiatric SAEs for hospitalization for disease worsening (i.e. schizophrenia, psychotic disorder), and suicidality leading to hospitalization were noted in the placebo arm versus none in any arm dosed with compound III (Table 9 in
FIG. 7 ). - These SAEs occurred in subjects in the placebo arm across geographic regions, in both males and females taking a number of different antipsychotic medications.
- These results show that by administration of compound III suicidal ideations, schizophrenia, relapses of schizophrenia and psychotic disorders can be successfully treated.
- Further, the efficacy in the above mentioned indications may be supported by clinical trials described below for prevention/delay of first episode of psychosis and/or treatment of attenuated psychosis syndrome:
- Regarding prevention of first episode of psychosis, the clinical trial disclosed below is in planning conducted to evaluate the efficacy, safety and tolerability of compound III given as an oral tablet during 52 weeks of treatment of 50 mg, twice daily (BID) compared to placebo in patients meeting diagnostic criteria for attenuated psychosis syndrome as defined in DSM-V. The study is designed to show superiority of compound III over placebo in preventing first episode of psychosis, as well as improvement in cognition and functional capacity.
- The study is a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel group design.
- Compound III (50 mg) and matching placebo is supplied as film-coated tablets (formulation 2).
- Patients who are 6 and 30 years old who meet diagnostic criteria for Attenuated Psychosis Syndrome (APS) per DSM-V as determined by the Structured Interview for Psychosis-Risk Syndromes (SIPS) will be screened using an algorithm developed by the North American Prodromal Longitudinal Study (NAPLS) consortia to select individuals predicted to be at greater than 35% risk of conversion to psychosis within the next 52 weeks.
-
- 1) Meet diagnostic criteria for attenuated psychosis syndrome as defined in DSM-V and determined by SIPS administered at screening, and diagnosis confirmed by Central Rating Committee after review of video-taped SIPS interview.
- 2) NAPLS risk calculator score ≥0.20 at screening indicative of greater than 35% risk of conversion to psychosis within the next 52 weeks.
- 3) Patients who are antipsychotic medication-naïve or who are currently taking an antipsychotic medication. If taking an antipsychotic medication, the dose can be decreased during the trial (or discontinued entirely), but the dose cannot be increased unless there is a significant worsening of psychosis symptoms.
- 4) Age ≥16 and ≤30 years at the time of consent/assent (if acceptable by local health authorities).
-
- 1) Present or past diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, bipolar disorder I or II, or major depressive disorder with psychotic symptoms according to DSM-V.
- 2) Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- 3) Any suicidal ideation of
type - 4) Known diseases of the central nervous system (including but not limited to any kind of seizures or stroke).
- 5) History of significant head injury (>5 minute without consciousness).
- 6) Diagnosis of a serious developmental disorder, mental retardation (documented IQ <70), cognitive disorder, or acute attenuated symptoms exclusively related to intoxication from a psychotropic substance.
- Patients eligible for the trial based on the aforementioned criteria may be assigned at random in a 1:1 ratio to one of 2 study arms (placebo bid, and 50 mg bid) and followed for 52 weeks of treatment.
- The results of the primary and key secondary efficacy endpoints and the primary and secondary safety endpoints are summarized below.
- The primary endpoint is time to first episode of psychosis within a 52 week timeframe. First episode of psychosis defined as:
- One or more of the following Positive Symptoms (Scale of Prodromal Symptoms (SOPS) criteria) in the psychotic range (rated at level 6):
-
- Unusual Thought Content/Delusional Ideas
- Suspiciousness/Persecutory Ideas
- Grandiosity
- Perceptual Abnormalities/Hallucinations
- Disorganized Communication
AND either a symptom is seriously disorganizing or dangerous OR one of the symptoms above occurred at least one hour per day at an average frequency of four days/week over the past month.
- A new prescription or increase in dose of an ongoing antipsychotic medication for worsening of psychosis symptoms.
- Time of onset of first episode psychosis is defined using the rater's best estimate as recorded in the Scale of Prodromal Symptoms (SOPS) interview or when the patient began taking a new prescription or increased the dose of antipsychotic medication.
-
-
- Change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) total score after 24 and 52 weeks of treatment
- Change from baseline in the neurocognitive composite score of Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) after 24 and 52 weeks of treatment
- Change from baseline in Positive and Negative Syndrome Scale (PANSS) positive items score, negative items score, and total score after 52 weeks of treatment.
- The primary safety endpoints are as follows:
-
- Occurrence of adverse events (AEs)/serious adverse events (including the abnormalities of physical examination, vital signs, electrocardiogram test and laboratory tests)
- Occurrence of protocol-specified adverse events of special interest
- Dramatic worsening of disease state as assessed by PANSS
- Suicidality as assessed by Columbia Suicidal Severity Rating Scale (C-SSRS)
- The secondary safety endpoint is the change in psychopathology symptoms as assessed by PANSS.
- For the primary endpoint of time to first episode of psychosis, the equality of the hazard rates will be tested by the Wald test for the treatment effect in a stratified Cox proportional hazards model at the two-sided 10% significance level. The model includes the treatment effect as the only covariate and is stratified by NAPLS risk calculator score and baseline use of antipsychotics. Secondary change from baseline endpoints will be analyzed using the restricted maximum likelihood (REML) based mixed effects model with repeated measurements (MMRM).
Claims (11)
1. A method of using Compound III
for treating, delaying or preventing a disorder selected from the group consisting of:
Schizophrenia spectrum and other psychotic disorders,
Schizophrenia,
Psychosis,
Schizotypal (personality) disorder,
Delusional disorder,
Attenuated psychosis syndrome,
Brief psychotic disorder,
Schizophreniform disorder,
Schizoaffective disorder,
Substance/Medication-Induced Psychotic Disorder,
Psychotic Disorder,
Psychotic Disorder Due to Another Medical Condition,
Other Specified Schizophrenia Spectrum and Other Psychotic Disorders,
Unspecified Schizophrenia Spectrum and Other Psychotic Disorder,
Catatonia Associated With Another Mental Disorder, and
Catatonic Disorder Due to Another Medical Condition, the method comprising administering a pharmaceutically effective amount of Compound III, or a pharmaceutically salt thereof, to a patient in need thereof.
2. The method according to claim 1 , where the method is for treating, delaying, or preventing a first episode and/or relapse of the disorder.
3. The method according to claim 1 for preventing the disorder.
4. The method according to claim 1 for treating attenuated psychosis syndrome.
5. The method according to claim 2 for reducing relapse in schizophrenia.
6. The method according to claim 1 for preventing first-episode of psychosis.
7. The method according to claim 1 , further comprising administering Compound III, or a pharmaceutically acceptable salt thereof, in combination with another antipsychotic drug.
8-9. (canceled)
10. The method of claim 1 for delaying the disorder.
11. The method of claim 2 for preventing the first episode and/or relapse of the disorder.
12. The method of claim 2 for delaying the first episode and/or relapse of the disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/145,430 US20210130362A1 (en) | 2017-02-23 | 2021-01-11 | Medical use of compound iii |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762462621P | 2017-02-23 | 2017-02-23 | |
US201762526393P | 2017-06-29 | 2017-06-29 | |
US15/900,823 US10919898B2 (en) | 2017-02-23 | 2018-02-21 | Medical use of compound III |
US17/145,430 US20210130362A1 (en) | 2017-02-23 | 2021-01-11 | Medical use of compound iii |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/900,823 Division US10919898B2 (en) | 2017-02-23 | 2018-02-21 | Medical use of compound III |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210130362A1 true US20210130362A1 (en) | 2021-05-06 |
Family
ID=61569222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/900,823 Active US10919898B2 (en) | 2017-02-23 | 2018-02-21 | Medical use of compound III |
US17/145,430 Pending US20210130362A1 (en) | 2017-02-23 | 2021-01-11 | Medical use of compound iii |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/900,823 Active US10919898B2 (en) | 2017-02-23 | 2018-02-21 | Medical use of compound III |
Country Status (11)
Country | Link |
---|---|
US (2) | US10919898B2 (en) |
EP (1) | EP3585392A1 (en) |
JP (1) | JP7053645B2 (en) |
KR (1) | KR102643197B1 (en) |
CN (1) | CN110325193B (en) |
AU (1) | AU2018225373C1 (en) |
CA (1) | CA3051976A1 (en) |
CL (1) | CL2019002315A1 (en) |
MX (1) | MX2019010003A (en) |
PH (1) | PH12019501926A1 (en) |
WO (1) | WO2018153887A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110082137A1 (en) * | 2009-03-31 | 2011-04-07 | Boehringer Ingelheim International Gmbh | New compounds for the treatment of cns disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008183929A (en) * | 2007-01-26 | 2008-08-14 | Toshiba Corp | Vor monitoring receiving apparatus and vor monitor receiving method |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
TWI404721B (en) * | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
EP3053924A1 (en) * | 2010-08-12 | 2016-08-10 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d]pyrimidin-4-one derivatives and their use as pde9a inhibitors |
JO3753B1 (en) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
CN107082783B (en) * | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | PDE9 inhibitor with imidazotriazinones skeleton |
IN2015DN00334A (en) * | 2012-06-18 | 2015-06-12 | Dart Neuroscience Cayman Ltd | |
WO2017019724A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
US10376504B2 (en) * | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
-
2018
- 2018-02-21 WO PCT/EP2018/054221 patent/WO2018153887A1/en unknown
- 2018-02-21 AU AU2018225373A patent/AU2018225373C1/en active Active
- 2018-02-21 CA CA3051976A patent/CA3051976A1/en active Pending
- 2018-02-21 JP JP2019545745A patent/JP7053645B2/en active Active
- 2018-02-21 MX MX2019010003A patent/MX2019010003A/en unknown
- 2018-02-21 EP EP18708929.7A patent/EP3585392A1/en active Pending
- 2018-02-21 KR KR1020197027682A patent/KR102643197B1/en active IP Right Grant
- 2018-02-21 CN CN201880012562.4A patent/CN110325193B/en active Active
- 2018-02-21 US US15/900,823 patent/US10919898B2/en active Active
-
2019
- 2019-08-16 CL CL2019002315A patent/CL2019002315A1/en unknown
- 2019-08-20 PH PH12019501926A patent/PH12019501926A1/en unknown
-
2021
- 2021-01-11 US US17/145,430 patent/US20210130362A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110082137A1 (en) * | 2009-03-31 | 2011-04-07 | Boehringer Ingelheim International Gmbh | New compounds for the treatment of cns disorders |
Non-Patent Citations (9)
Title |
---|
Campbell (Year: 1999) * |
Dorner-Ciosesek (Year: 2015) * |
Moschetti (Year: 2016) * |
NCT01343706 (Year: 2011) * |
NCT01892384 (Year: 2013) * |
NCT02281773 (Year: 2014) * |
PubChemCID135908617 (Year: 2019) * |
Rosenbrock (Year: 2015) * |
Tang (Year: 2016) * |
Also Published As
Publication number | Publication date |
---|---|
CN110325193B (en) | 2023-05-05 |
AU2018225373C1 (en) | 2022-05-12 |
CA3051976A1 (en) | 2018-08-30 |
CN110325193A (en) | 2019-10-11 |
KR20190120298A (en) | 2019-10-23 |
CL2019002315A1 (en) | 2019-12-27 |
JP2020508320A (en) | 2020-03-19 |
US20180237445A1 (en) | 2018-08-23 |
KR102643197B1 (en) | 2024-03-06 |
AU2018225373A1 (en) | 2019-08-01 |
AU2018225373B2 (en) | 2022-02-03 |
MX2019010003A (en) | 2019-12-16 |
PH12019501926A1 (en) | 2020-07-06 |
JP7053645B2 (en) | 2022-04-12 |
EP3585392A1 (en) | 2020-01-01 |
US10919898B2 (en) | 2021-02-16 |
WO2018153887A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2767285B1 (en) | TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF | |
KR20190077561A (en) | Crystalline form of MAGL inhibitor | |
TWI694069B (en) | Pharmaceutical formulation for treating schizophrenia | |
NO342977B1 (en) | Racecadotril tablet, method of preparing such and such tablets for the treatment of diarrhea | |
US20130183384A1 (en) | Immediate release multi unit pellet system | |
US20230157947A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
US20230293495A1 (en) | Pharmaceutical formulations for treating diseases mediated by kdm1a | |
US20210130362A1 (en) | Medical use of compound iii | |
EA042977B1 (en) | USE OF COMPOUND III FOR THE TREATMENT OF SCHIZOPHRENIC SPECTRUM DISEASES AND OTHER PSYCHOTIC DISORDERS | |
US8309607B2 (en) | Rapid release irbesartan-containing pharmaceutical composition | |
US11331283B2 (en) | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders | |
RU2810575C1 (en) | Pharmaceutical composition, including memantine and citicoline, and also a dosage form based on specified pharmaceutical composition, including memantine and citicoline, method of its obtaining and use of dosage form based on pharmaceutical ceutic composition, including memantine and citicoline | |
US20230381123A1 (en) | Compositions Containing Dofetilide and Mexiletine and Uses Thereof | |
WO2015067313A1 (en) | Orodispersible pharmaceutical compositions comprising aripiprazole | |
EP1686965A2 (en) | Solid pharmaceutical preparation form | |
JPH09249563A (en) | Tizanidin-containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |